DPH.L - Dechra Pharmaceuticals PLC

LSE - LSE Delayed price. Currency in GBp
2,782.00
+14.00 (+0.51%)
As of 2:16PM BST. Market open.
Stock chart is not supported by your current browser
Previous close2,768.00
Open2,750.00
Bid2,780.00 x N/A
Ask2,782.00 x N/A
Day's range2,720.00 - 2,794.00
52-week range1,992.00 - 3,180.00
Volume126,248
Avg. volume205,616
Market cap2.855B
Beta (3Y monthly)0.48
PE ratio (TTM)114.96
EPS (TTM)24.20
Earnings date2 Sep 2019 - 6 Sep 2019
Forward dividend & yield0.28 (1.01%)
Ex-dividend date2019-03-07
1y target est2,680.86
  • Announcing: Dechra Pharmaceuticals (LON:DPH) Stock Increased An Energizing 287% In The Last Five Years
    Simply Wall St.17 days ago

    Announcing: Dechra Pharmaceuticals (LON:DPH) Stock Increased An Energizing 287% In The Last Five Years

    The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

  • Is Dechra Pharmaceuticals PLC's (LON:DPH) ROE Of 4.9% Concerning?
    Simply Wall St.last month

    Is Dechra Pharmaceuticals PLC's (LON:DPH) ROE Of 4.9% Concerning?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Is Dechra Pharmaceuticals PLC's (LON:DPH) CEO Paid At A Competitive Rate?
    Simply Wall St.2 months ago

    Is Dechra Pharmaceuticals PLC's (LON:DPH) CEO Paid At A Competitive Rate?

    In 2001 Ian Page was appointed CEO of Dechra Pharmaceuticals PLC (LON:DPH). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, we will consider...

  • Reuters - UK Focus3 months ago

    BUZZ-Dechra Pharma: "Diamond in the Ruff" - JPM starts with OW

    ** JP Morgan starts UK-based animal health co Dechra Pharmaceuticals with "overweight" and PT 3,000p ** Brokerage sees Animal Health as attractive subsector offering strong demographic demand, ...

  • Reuters - UK Focus4 months ago

    Ex-divs to take 21.7 points off FTSE 100 on March 7

    The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the latest dividend payout. According to Reuters calculations at current market prices, ...

  • Should Dechra Pharmaceuticals PLC (LON:DPH) Be Part Of Your Income Portfolio?
    Simply Wall St.5 months ago

    Should Dechra Pharmaceuticals PLC (LON:DPH) Be Part Of Your Income Portfolio?

    Dividends play an important role in compounding returns in the long run and end up forming a sizeable part of investment returns. Historically, Dechra Pharmaceuticals PLC (LON:DPH) has paid dividends Read More...

  • Read This Before Buying Dechra Pharmaceuticals PLC (LON:DPH) Shares
    Simply Wall St.6 months ago

    Read This Before Buying Dechra Pharmaceuticals PLC (LON:DPH) Shares

    It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have Read More...

  • Simply Wall St.6 months ago

    Is Dechra Pharmaceuticals PLC’s (LON:DPH) ROE Of 7.1% Concerning?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...

  • What Do Analysts Think About Dechra Pharmaceuticals PLC’s (LON:DPH) Earnings Trajectory?
    Simply Wall St.7 months ago

    What Do Analysts Think About Dechra Pharmaceuticals PLC’s (LON:DPH) Earnings Trajectory?

    The latest earnings announcement Dechra Pharmaceuticals PLC (LON:DPH) released in June 2018 indicated that the business benefited from a robust tailwind, leading to a double-digit earnings growth of 38%. Investors Read More...

  • Simply Wall St.8 months ago

    Is Dechra Pharmaceuticals PLC’s (LON:DPH) CEO Paid Enough Relative To Peers?

    In 2001 Ian Page was appointed CEO of Dechra Pharmaceuticals PLC (LON:DPH). First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth that Read More...

  • Reuters - UK Focus8 months ago

    Ex-divs to take 1.3 points off FTSE 100 on Oct 25

    The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the latest dividend payout. According to Reuters calculations at current market prices, ...

  • Simply Wall St.9 months ago

    Does Dechra Pharmaceuticals PLC’s (LON:DPH) PE Ratio Warrant A Sell?

    I am writing today to help inform people who are new to the stock market and want to learn about the link between company’s fundamentals and stock market performance. Dechra Read More...

  • Is Dechra Pharmaceuticals plc (LON:DPH) Expensive For A Reason? A Look At The Intrinsic Value
    Simply Wall St.9 months ago

    Is Dechra Pharmaceuticals plc (LON:DPH) Expensive For A Reason? A Look At The Intrinsic Value

    Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Dechra Pharmaceuticals plc (LON:DPH) as an investment opportunity by taking theRead More...

  • Reuters10 months ago

    European shares flat amid trade and emerging market worries

    European shares ended little changed on Monday as worries about U.S. trade policy and concern over emerging markets weighed on stocks after Asian markets closed lower. The pan-European STOXX 600 (.STOXX) index gained 0.05 percent to 382.46 points. Activity was subdued as U.S. markets were closed for Labor Day.

  • The Telegraph10 months ago

    Dechra's shares slump as it warns of costs for Brexit contingency plans

    Dechra's shares slump as it warns of costs for Brexit contingency plans

  • U.K. Pet Drugmaker Dechra Sparks Share Tumble With Brexit Plans
    Bloomberg10 months ago

    U.K. Pet Drugmaker Dechra Sparks Share Tumble With Brexit Plans

    Dechra Pharmaceuticals Plc, a maker of animal medicines, is looking at setting up dual testing facilities in the U.K. and European Union in preparation for Brexit, a sign companies are stepping up their contingency plans as politicians stumble over a future deal. The veterinary company sparked concern on Monday when it said it may need to spend as much as 2 million pounds ($2.6 million) in the event of a hard Brexit, in part to duplicate testing and move product registrations to the EU to avoid trade barriers. Most companies in the U.K. are preparing contingency plans as the British government and EU officials struggle to reach a deal over what their future relationship will look like.

  • Reuters10 months ago

    Dechra Pharma says to implement hard Brexit plan

    The company listed Brexit along with U.S. sanctions on Iran and the European Union challenging the legality of the UK Control Foreign Company (CFC) tax legislation as three emerging geopolitical risks to its business. Results for the FTSE 250-listed firm showed revenue rose 13.9 percent to 407.1 million pounds at constant currency for the year-ended June 30.

  • Reuters - UK Focus10 months ago

    UK's Dechra Pharma says to implement hard Brexit plan

    Veterinary drugs producer Dechra Pharmaceuticals said on Monday it was moving ahead with plans for a hard Brexit, stressing the financial impact should be "immaterial" but spooking investors worried about revenue and operations after next year's split. Shares (Berlin: DI6.BE - news) of the company plunged around 20 percent to a more than six-month low to 2,454 pence in early trading on the London Stock Exchange. "This includes transferring UK registered Marketing Authorisations for products that are sold in the EU to an EU entity and duplication of product release testing for products that are transferred between the UK and the EU," it said.

  • Dechra Pharmaceuticals plc (LON:DPH): Time For A Financial Health Check
    Simply Wall St.10 months ago

    Dechra Pharmaceuticals plc (LON:DPH): Time For A Financial Health Check

    Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Dechra Pharmaceuticals plc (LON:DPH) with a market-capitalization of UK£3.19b, rarely draw their attention. Despite this, the twoRead More...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes